Volvo Group acquires NOVO R&D’s battery lab to boost green transformation

Martin Lundstedt President and CEO Volvo Group
Martin Lundstedt President and CEO - Volvo Group
0Comments

Volvo Group has announced the acquisition of a cutting-edge battery cell laboratory from NOVO Energy AB. This move is part of Volvo’s ongoing efforts to advance its green transformation and support the development of sustainable transport solutions.

The acquisition, effective from July 1, 2025, includes taking over the battery cell chemistry and material research team and facilities. The staff from NOVO R&D will be integrated into Volvo Group’s organization while remaining at their current location in Gothenburg.

Lars Stenqvist, CTO of Volvo Group, stated: “The acquisition means that this top-class competence will remain in Gothenburg and Sweden, strengthening the region’s competitiveness in clean technology. This is a great opportunity for us to further enhance our competence in battery cell chemistry and material research areas. It will be a very strong asset to succeed with our strategy towards being 100% fossil-free in 2040.”

For additional information, journalists can contact Claes Eliasson, Head of Media Relations at +46 76 553 7229 or via email at [email protected]. More details are available on volvogroup.com.

Volvo Group provides various transport and infrastructure solutions including trucks, buses, construction equipment, power solutions for marine and industrial applications, as well as financing services. Established in 1927 and headquartered in Gothenburg, Sweden, Volvo employs over 100,000 people worldwide. In 2024, its net sales reached SEK 527 billion (EUR 46 billion). The company’s shares are traded on Nasdaq Stockholm.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.